HYC 750

Drug Profile

HYC 750

Alternative Names: HYC750; ORC-HYC750

Latest Information Update: 08 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Alberta
  • Developer Orcrist Bio
  • Class
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Anaemia; Neutropenia

Most Recent Events

  • 06 Apr 2009 The European Competent Authority in Spain approves a phase I trial of HYC 750 in healthy volunteers
  • 09 Feb 2009 Orcrist Bio files for phase I clinical trial in Spain
  • 04 Apr 2007 HYC 750 is still in phase I trials for cancer-related Anaemia and Neutropenia in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top